Nektar Branches Out In Pain, Hails Next Generation Of Analgesics

At R&D event, company signals shift of Phase III for lead pain drug NKTR-181 to mid-2014 from earlier in the year. Nektar also featured crop of new drugs targeted at different molecular pathways, including NKTR-192, a partial agonist for acute pain, and a new kind of sodium channel blocker called NKTR-171 for neuropathy.